A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma (DMV)

This study has been withdrawn prior to enrollment.
(low accrual)
Sponsor:
Information provided by:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00516191
First received: August 13, 2007
Last updated: June 21, 2011
Last verified: June 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: December 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)